Journal of Clinical Oncology
Articles in this Issue
Updated efficacy results from the phase 1 study of gotistobart (BNT316/ONC-392) in combination with lutetium Lu 177 vipivotide tetraxetan (Lu 177) in patients with metastatic castration-resistant prostate cancer (mCRPC).
175 Background: Lutetium-177 vipivotide tetraxetan (Lu 177) significantly improves progression-free survival (PFS) and ove...
Circulating tumor DNA (ctDNA) to guide response-adapted bladder preservation in muscle invasive bladder cancer (MIBC): Integrated analysis of the RETAIN trials.
LBA632 Background: The phase II RETAIN 1 and 2 trials evaluated a response-adapted approach to identify pts with MIBC who...
Bleeding risk with concurrent anticoagulation and VEGF-TKI therapy in mRCC: A real-world TriNetX analysis.
485 Background: Metastatic renal cell carcinoma (mRCC) is associated with both thromboembolic and hemorrhagic complication...
Ultra-sensitive whole-genome sequencing-based molecular residual disease detection in resectable renal cell carcinoma: Preliminary results from the MONSTAR-SCREEN-3 study.
421 Background: Circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) detection has shown promise across va...
Maintenance zanzalintinib with oral etoposide following high-dose chemotherapy in patients with relapsed metastatic germ-cell tumor (GCT).
TPS626 Background: While most patients (pts) with metastatic GCTs are cured with first line cisplatin-based chemotherapy,...
Real-world time to next treatment in metastatic urothelial cancer patients: Enfortumab vedotin and pembrolizumab vs chemotherapy as first-line treatment.
707 Background: Since 2023, the combination of enfortumab vedotin and pembrolizumab (EV+P) has become a first-line (1L) no...
Comprehensive analysis of androgen production, uptake, and conversion (APUC) genes to highlight SRD5 family diversity in a large localized prostate cancer cohort.
382 Background: Androgen receptor signaling drives prostate cancer (PC) progression, and genes involved in androgen produc...
<i>VHL</i> wild-type clinically advanced clear cell renal cell carcinoma (ccRCC): A genomic landscape study.
533 Background: The most common alteration in both early and late stage ccRCC is of the von-Hippel Lindau (...
Development of a putative liquid biopsy gene panel for predicting liver metastasis in castration-resistant prostate cancer.
226 Background: Liver metastases (LM) in prostate cancer (PCa) while considered rare, are associated with poor clinical ou...
Integrating genomic prognostic and hallmark signatures from Decipher GRID to predict adverse outcomes in men on active surveillance for prostate cancer.
402 Background: Active surveillance (AS) has been accepted as the standard management for lower-risk prostate cancer (PCa)...
Comparative real-world survival and prescription patterns of darolutamide versus apalutamide in non-metastatic hormone-resistant prostate cancer.
129 Background: Androgen receptor pathway inhibitors (ARPIs) improve metastasis-free and overall survival in men with non-...
Immunological clustering from peripheral blood to define prognosis and T cell exhaustion profiles in renal cell carcinoma.
536 Background: Peripheral blood markers such as neutrophil-to-lymphocyte ratio (NLR) and CRP are established prognostic f...
Comparative outcomes of chemoradiotherapy regimens in muscle-invasive bladder cancer: A retrospective cohort study.
738 Background: Bladder-preserving chemoradiotherapy (CRT) is an organ-sparing alternative to radical cystectomy for muscl...
Prognosis of patients (pts) with synchronous vs metachronous metastatic or locally advanced urothelial carcinoma (la/mUC).
695 Background: There is relatively limited data regarding the prognostic role of...
Quality of life, adherence, and adverse events among patients with advanced prostate cancer treated with relugolix: 6-month results of the OPTYX multicenter registry.
122 Background: Relugolix is the only oral androgen deprivation therapy FDA approved for advanced prostate cancer (PC), ba...
Surveillance of patients with complete response following first-line chemotherapy for germ cell tumors: Focus on lifestyle, socioeconomic, and sexual health outcomes.
608 Background: Advances in multimodal therapy have transformed germ cell tumors (GCTs) into a highly curable malignancy,...
Enhancing the molecular assessment of MRI targeted prostate biopsies utilizing near real time stimulated Raman histology and artificial intelligence.
384 Background: Stimulated Raman histology (SRH) produces rapid, label-free optical sections of fresh tissue that can be i...
Sequencing of therapeutic agents before and after metastatic castration-resistant prostate cancer (mCRPC) diagnosis in an international real-world setting.
100 Background: Over the last decade, many new approaches to mCRPC management have evolved. However, information is lackin...
A feasibility trial investigating inductive apalutamide therapy combined with radical prostatectomy in patients with locally advanced T4 high risk prostate cancer: First results of the prospective phase II INDUCTA study.
370 Background: Locally-advanced, inoperable T4 prostate cancer (PCa) is a challenging scenario usually treated by combine...
Association of non-luminal subtype with overall survival in high-risk non-muscle invasive bladder cancer patients: Biomarker results from the Bladder Cancer Prognosis Programme.
843 Background: High-risk non-muscle-invasive bladder cancer (HR-NMIBC) is associated with substantial progression and rec...
Concordance between clinical, genomic, and AI-based risk stratification in prostate cancer.
388 Background: An expanding number of tests utilizing clinical criteria, genomic classifiers, and machine learning are av...
Skeletal muscle index as a prognostic and predictive biomarker in de novo hormone sensitive prostate cancer: An exploratory analysis of the STAMPEDE trials.
173 Background: Sarcopenia is common in advanced prostate cancer and worsened by androgen deprivation therapy (ADT). Routi...
Deep spatial analysis of the tumor-immune interface in localized prostate cancer.
377 Background: Prostate cancer (PC) has been historically considered immunologically “cold” due to low immune infiltratio...
A phase II study of zanzalintinib for patients with advanced urothelial carcinoma following prior therapy.
TPS889 Background: Advanced urothelial carcinoma (aUC) remains an aggressive malignancy with limited options in refractory...
Bone fractures with androgen pathway inhibitors (ARPi) in patients (pts) with prostate cancer (PCa): A systematic review and network meta-analysis.
144 Background: Androgen receptor pathway inhibitors (abiraterone acetate [AAP], apalutamide [APA], enzalutamide [E], daro...